Outcomes of Participants With Diabetes in the ISCHEMIA Trials
Authors: Newman Jonathan D. , Anthopolos Rebecca , Mancini G.B. John , Bangalore Sripal , Reynolds Harmony R. , Kunichoff Dennis F. , Senior Roxy , Peteiro Jesus , Bhargava Balram , Garg Pallav , Escobedo Jorge , Doerr Rolf , Mazurek Tomasz , Gonzalez-Juanatey Jose , Gajos Grzegorz , Briguori Carlo , Cheng Hong , Vertes Andras , Mahajan Sandeep , Guzman Luis A. , Keltai Matyas , Maggioni Aldo P. , Stone Gregg W. , Berger Jeffrey S. , Rosenberg Yves D. , Boden William E. , Chaitman Bernard R. , Fleg Jerome L. , Hochman Judith S. , Maron David J. 
Published: September 2021

Background:
Among patients with diabetes and chronic coronary disease, it is unclear if invasive management improves outcomes when added to medical therapy.

Methods:
The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trials (ie, ISCHEMIA and ISCHEMIA–Chronic Kidney Disease) randomized chronic coronary disease patients to an invasive (medical therapy + angiography and revascularization if feasible) or a conservative approach (medical therapy alone with revascularization if medical therapy failed). Cohorts were combined after no trial-specific effects were observed. Diabetes was defined by history, hemoglobin A1c ≥6.5%, or use of glucose-lowering medication. The primary outcome was all-cause death or myocardial infarction (MI). Heterogeneity of effect of invasive management on death or MI was evaluated using a Bayesian approach to protect against random high or low estimates of treatment effect for patients with versus without diabetes and for diabetes subgroups of clinical (female sex and insulin use) and anatomic features (coronary artery disease severity or left ventricular function).

Results:

Of 5900 participants with complete baseline data, the median age was 64 years (interquartile range, 57–70), 24% were female, and the median estimated glomerular filtration was 80 mL·min
−1
·1.73
−2
(interquartile range, 64–95). Among the 2553 (43%) of participants with diabetes, the median percent hemoglobin A1c was 7% (interquartile range, 7–8), and 30% were insulin-treated. Participants with diabetes had a 49% increased hazard of death or MI (hazard ratio, 1.49 [95% CI, 1.31–1.70];
P
<0.001). At median 3.1-year follow-up the adjusted event-free survival was 0.54 (95% bootstrapped CI, 0.48–0.60) and 0.66 (95% bootstrapped CI, 0.61–0.71) for patients with diabetes versus without diabetes, respectively, with a 12% (95% bootstrapped CI, 4%–20%) absolute decrease in event-free survival among participants with diabetes. Female and male patients with insulin-treated diabetes had an adjusted event-free survival of 0.52 (95% bootstrapped CI, 0.42–0.56) and 0.49 (95% bootstrapped CI, 0.42–0.56), respectively. There was no difference in death or MI between strategies for patients with diabetes versus without diabetes, or for clinical (female sex or insulin use) or anatomic features (coronary artery disease severity or left ventricular function) of patients with diabetes.

Conclusions:
Despite higher risk for death or MI, chronic coronary disease patients with diabetes did not derive incremental benefit from routine invasive management compared with initial medical therapy alone.

Registration:

URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT01471522.